Clinical Trials Logo

Penile Neoplasms clinical trials

View clinical trials related to Penile Neoplasms.

Filter by:

NCT ID: NCT05686226 Recruiting - Cervical Cancer Clinical Trials

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Start date: March 7, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

NCT ID: NCT05662839 Not yet recruiting - Penile Cancer Clinical Trials

Feasibility of Utilising Brushing Cytology and Dermoscopy for Diagnosing Penile Lesions

BRUCY
Start date: January 2023
Phase: N/A
Study type: Interventional

In an attempt to reduce patient flow into the hospital we are going to assess the use of penile cytological brushings and dermoscopy in diagnosing cancer or non-cancer conditions of the penis.

NCT ID: NCT05639972 Not yet recruiting - Cervical Cancer Clinical Trials

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Start date: June 12, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival. This study seeks to determine 1) if E7 TCR-T cell can be administered without undue delay in definitive treatment, 2) the tumor response rate to E7 TCR-T cell treatment, 3) and the disease-free survival rate at 2 and 5 years. Participants will undergo an apheresis procedure to obtain T cells that will be genetically engineered to generate E7 TCR-T cells. They will receive a conditioning regimen, a single infusion of their own E7 TCR-T cells, and adjuvant aldesleukin. Participants will follow up to assess safety and determine tumor response and will return to their primary oncology team for definitive therapy.

NCT ID: NCT05592639 Recruiting - Melanoma Clinical Trials

VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer

VELRAD
Start date: June 23, 2022
Phase: N/A
Study type: Interventional

Assess the feasibility of performing a RCT comparing videoendoscopic radical inguinal lymphadenectomy versus open radical inguinal lymphadenectomy in men diagnosed with genital cancer requiring inguinal lymphadenectomy, and determine the design of such an RCT.

NCT ID: NCT05578820 Recruiting - Melanoma Clinical Trials

Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Start date: January 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of different doses and administration regimens of Stimotimagene copolymerplasmid in patients with histologically confirmed diagnosis of solid tumor and/or its metastases.

NCT ID: NCT05526989 Recruiting - Penile Carcinoma Clinical Trials

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Start date: December 28, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.

NCT ID: NCT05518201 Completed - Anal Cancer Clinical Trials

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Start date: September 23, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.

NCT ID: NCT05447273 Recruiting - Penile Cancer Clinical Trials

The Role of Functional Magnetic Resonance Imaging in Preoperative Assessment of Primary Penile Carcinoma

Start date: July 15, 2022
Phase:
Study type: Observational

The proposed project is intended as a prospective study that includes 60 patients with newly diagnosed penile squamous cell carcinoma (SCC) referred to Oslo University Hospital (OUH), Radiumhospitalet, for surgery, primarily organ-sparing surgery (OSS). OSS may improve not only quality of life, but also quality of sexual function. However, there is a potential for increased risk of local recurrence after OSS compared to the amputation of the penis. Appropriate preoperative staging, including multi-parametric magnetic resonance imaging (mpMRI), can substantially improve selection of patients and decrease the recurrence rate after surgery. MpMRI without artificial erection is promising diagnostic tool that is poised to be all-in-one solution for staging and preoperative assessment of primary penile cancer, especially prior to OSS. The method is non-invasive and thus comfortable to perform for most of the patients. Novel MRI techniques are not incorporated into current clinical recommendations, and the potential of new, functional sequences has not been evaluated before. The accuracy of functional, non-erectile mpMRI for detecting and staging of primary penile cancer is not known. Thus, the main purpose of this study is to assess the diagnostic value of this method for preoperative assessment of penile cancer.

NCT ID: NCT05376202 Completed - Penile Cancer Clinical Trials

Image Guided Penile Cancer Surgery

GLANS
Start date: March 7, 2022
Phase: Phase 1
Study type: Interventional

The main treatment modality for Penile Squamous Cell Carcinoma (PSCC) is surgery with curative intent. In organ sparing surgery a tumor-positive margin of up to 36% exist. Tumor-positive surgical margins are an independent risk factor for local recurrence, which has been reported to be up to 18%. Tumor-positive margins always lead to extra, penile sparing surgery, which leads to longer hospitalization, higher exposure to anesthetic interventions and a worse psychological outcome. Currently, no intraoperative imaging technique that provides real time feedback for resection margins exists in PSCC. Molecular fluorescence-guided Surgery (MFGS) using targeted near-infrared (NIR) optical contrast agents like for example Cetuximab-800CW is a promising technique to accommodate this need. Epidermal Growth Factor Receptor (EGFR) is overexpressed in PSCC and has safely and successfully been used as target for molecular imaging, particularly for assessment for tumor margins in head and neck squamous cell carcinoma (ICON study, UMCG1).

NCT ID: NCT05264337 Recruiting - Prostatic Neoplasms Clinical Trials

Lymphedema After Urologic Surgery

Start date: March 14, 2022
Phase:
Study type: Observational

Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic surgery with lymph node dissection. This project aims to describe the frequency and grade of lymphedema arising after urologic surgery, using the Lymphedema Quality of Life Questionnaire (LymQOL), Delfin MoistureMeter D, and lower limb volume measurements.